



17 Jan 2019

The Health, Malaysia

Author: No author available • Section: News • Page: 4 • Printed size: 77.00cm²
Region: KL • Market: Malaysia • Photo: Full Color • ASR: MYR 1,066.00
Item ID: MY0034871771

 isentia.mediaportal

Provided for client's internal research purposes only. May not be further copied, distributed, sold or published in any form without the prior consent of the copyright owner.

Page 1 of 2

Malaysian breakthrough in clinical study on ovarian cancer blood test

“MALAYSIA is the first country in Asia to start clinical study of ovarian cancer diagnostic blood test in early 2019,” said Chief Executive Officer of Clinical Research Malaysia, Dr Akhmal Yusof.

This is following an institutional investment of RM39 million by InterVenn BioSciences, a biotech company based in the US to develop the cancer early detection blood test in collaboration with CRM and Technology Park Malaysia (TPM).

TPM acting TPM acting president/CEO, Sharbani Harun said that the collaboration marked an important milestone for Malaysia to become a central hub for the Asia-Pacific region, towards the advancement of research and development in the field of biomedical and life sciences.

Meanwhile, Dr. Akhmal added InterVenn's decision to conduct clinical study here is a testament to the country's capabilities in terms of infrastructure, good clinical practice, certified investigators and a large patient pool.

Once clinical validation and regulatory processes are completed, the ovarian cancer blood test will be offered as a laboratory diagnostic test.



17 Jan 2019

The Health, Malaysia

Author: No author available • Section: News • Page: 4 • Printed size: 77.00cm²
Region: KL • Market: Malaysia • Photo: Full Color • ASR: MYR 1,066.00
Item ID: MY0034871771

 isentia.mediaportal

Provided for client's internal research purposes only. May not be further copied, distributed, sold or published in any form without the prior consent of the copyright owner.

Page 2 of 2

SUMMARIES

“Malaysia is the first country in Asia to start clinical study of ovarian cancer diagnostic blood test in early 2019,” said Chief Executive Officer of Clinical Research Malaysia, Dr Akhmal Yusof. This is following an institutional investment of RM39 million by InterVenn BioSciences, a biotech company based in the US to develop the cancer early detection blood test in collaboration with CRM and Technology Park Malaysia (TPM).